Related Experiment Video
Updated: Jun 5, 2026
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
11.7K
A Retrospective Analysis of Ambiguous Spitz Tumors Using Next-Generation Sequencing
Mario Teufer1,2, Martin Theiler2,3, Joana Lanz2,3,4
1Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland.
Cancers
|April 14, 2025
Summary
Next-generation sequencing (NGS) and immunohistochemistry (IHC) improve Spitz tumor (ST) diagnosis. Combining these methods helps differentiate benign Spitz nevi from atypical Spitz tumors and Spitz melanoma, guiding risk assessment and patient management.
Area of Science:
- Dermatopathology
- Oncology
- Molecular Diagnostics
Background:
- Spitz tumors (STs) present diagnostic challenges due to overlapping features and variable malignant potential.
- Histological and immunohistochemical (IHC) analyses alone are often insufficient for accurate ST classification.
- Distinguishing benign from malignant melanocytic lesions is crucial for appropriate clinical management.
Purpose of the Study:
- To evaluate the diagnostic utility of a melanoma-specific next-generation sequencing (NGS) panel (MelArray) combined with IHC.
- To improve the assessment of diagnostically challenging Spitz tumor cases.
- To correlate molecular and IHC findings with patient outcomes.
Main Methods:
- Retrospective analysis of patients with Spitz tumors and available MelArray NGS results.
- Evaluation of molecular alterations (genetic mutations, TMB, CNV), IHC scores (p16, Ki-67, HMB45, PRAME, Melan A), and clinical data.
- Correlation of integrated diagnostic data with patient follow-up and outcomes.
Main Results:
- Atypical Spitz tumors (ASTs) showed heterozygous deletions but lacked multiple damaging mutations typical of melanoma.
- Spitz nevi (SN) exhibited minimal genetic alterations and low IHC scores, consistent with a benign profile.
- Spitz melanoma (SM) displayed a distinct molecular profile with damaging mutations, high TMB, and IHC scores similar to ASTs.
Conclusions:
- Integrating NGS (MelArray panel) with histology and IHC enhances diagnostic accuracy for challenging STs.
- This combined approach identifies genetic alterations associated with malignancy risk, aiding in risk stratification.
- The findings support improved detection of high-risk lesions requiring closer follow-up and better prediction of benign courses.
